Concepts (104)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hematopoietic Stem Cell Transplantation | 18 | 2024 | 878 | 2.750 |
Why?
|
| Leukemia, Myeloid, Acute | 5 | 2024 | 763 | 1.400 |
Why?
|
| Hematologic Neoplasms | 6 | 2023 | 329 | 1.230 |
Why?
|
| Transplantation Conditioning | 6 | 2020 | 373 | 1.150 |
Why?
|
| Myelodysplastic Syndromes | 2 | 2024 | 346 | 0.900 |
Why?
|
| Transplantation, Homologous | 9 | 2021 | 996 | 0.870 |
Why?
|
| Antigens, CD34 | 3 | 2017 | 158 | 0.760 |
Why?
|
| Transplantation, Haploidentical | 1 | 2017 | 27 | 0.600 |
Why?
|
| Neoplasm, Residual | 1 | 2018 | 162 | 0.600 |
Why?
|
| Unrelated Donors | 1 | 2017 | 50 | 0.580 |
Why?
|
| Donor Selection | 1 | 2017 | 67 | 0.570 |
Why?
|
| Graft vs Host Disease | 5 | 2023 | 365 | 0.560 |
Why?
|
| Cord Blood Stem Cell Transplantation | 1 | 2017 | 93 | 0.550 |
Why?
|
| Multiple Myeloma | 4 | 2021 | 307 | 0.510 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2018 | 456 | 0.510 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 5 | 2023 | 2438 | 0.470 |
Why?
|
| Hodgkin Disease | 1 | 2014 | 177 | 0.440 |
Why?
|
| Mutation | 4 | 2023 | 3968 | 0.430 |
Why?
|
| Biomarkers, Tumor | 2 | 2018 | 1464 | 0.390 |
Why?
|
| Tumor Suppressor Protein p53 | 2 | 2024 | 381 | 0.360 |
Why?
|
| Long Term Adverse Effects | 2 | 2017 | 6 | 0.310 |
Why?
|
| Humans | 27 | 2024 | 86643 | 0.250 |
Why?
|
| Medical Futility | 1 | 2024 | 28 | 0.240 |
Why?
|
| Prospective Studies | 3 | 2024 | 4213 | 0.240 |
Why?
|
| Neoplasm Recurrence, Local | 4 | 2023 | 1313 | 0.230 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 2023 | 151 | 0.210 |
Why?
|
| Geriatric Assessment | 2 | 2020 | 166 | 0.210 |
Why?
|
| Jehovah's Witnesses | 1 | 2021 | 18 | 0.190 |
Why?
|
| Aged | 10 | 2020 | 18415 | 0.190 |
Why?
|
| Neoplasms, Germ Cell and Embryonal | 1 | 2020 | 47 | 0.190 |
Why?
|
| Aminopyridines | 1 | 2020 | 38 | 0.180 |
Why?
|
| Isocitrate Dehydrogenase | 1 | 2020 | 51 | 0.180 |
Why?
|
| Triazines | 1 | 2020 | 53 | 0.180 |
Why?
|
| Neutrophils | 1 | 2021 | 307 | 0.180 |
Why?
|
| Middle Aged | 11 | 2020 | 25028 | 0.180 |
Why?
|
| Immunotherapy, Adoptive | 2 | 2023 | 170 | 0.170 |
Why?
|
| Interdisciplinary Communication | 1 | 2019 | 130 | 0.170 |
Why?
|
| Adult | 10 | 2023 | 25648 | 0.170 |
Why?
|
| Transplantation, Autologous | 4 | 2021 | 331 | 0.170 |
Why?
|
| Myeloproliferative Disorders | 1 | 2020 | 110 | 0.160 |
Why?
|
| Neoplasms, Second Primary | 1 | 2020 | 252 | 0.160 |
Why?
|
| Mitoxantrone | 1 | 2018 | 68 | 0.160 |
Why?
|
| Disease Management | 1 | 2019 | 327 | 0.150 |
Why?
|
| Cytarabine | 1 | 2018 | 218 | 0.150 |
Why?
|
| Preoperative Care | 1 | 2019 | 397 | 0.150 |
Why?
|
| Chromosome Duplication | 1 | 2017 | 8 | 0.150 |
Why?
|
| Patient Care Team | 1 | 2019 | 280 | 0.150 |
Why?
|
| Histocompatibility | 1 | 2017 | 71 | 0.150 |
Why?
|
| Chromosomes, Human, Pair 1 | 1 | 2017 | 100 | 0.150 |
Why?
|
| Echocardiography | 1 | 2021 | 911 | 0.140 |
Why?
|
| Survivors | 1 | 2017 | 226 | 0.140 |
Why?
|
| Stem Cell Transplantation | 3 | 2021 | 183 | 0.130 |
Why?
|
| Young Adult | 2 | 2017 | 5976 | 0.130 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 316 | 0.130 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 301 | 0.130 |
Why?
|
| Female | 11 | 2020 | 44532 | 0.120 |
Why?
|
| Pandemics | 1 | 2020 | 740 | 0.120 |
Why?
|
| Male | 10 | 2020 | 40965 | 0.120 |
Why?
|
| Treatment Outcome | 3 | 2020 | 7993 | 0.100 |
Why?
|
| Gastrointestinal Microbiome | 1 | 2017 | 455 | 0.100 |
Why?
|
| Signal Transduction | 1 | 2020 | 3241 | 0.090 |
Why?
|
| Survival Analysis | 3 | 2017 | 1538 | 0.090 |
Why?
|
| Adolescent | 2 | 2020 | 8981 | 0.080 |
Why?
|
| Retrospective Studies | 4 | 2023 | 8489 | 0.070 |
Why?
|
| Antineoplastic Agents | 1 | 2018 | 2360 | 0.070 |
Why?
|
| Remission Induction | 2 | 2018 | 722 | 0.070 |
Why?
|
| Australia | 1 | 2023 | 99 | 0.060 |
Why?
|
| Melphalan | 1 | 2023 | 98 | 0.060 |
Why?
|
| fms-Like Tyrosine Kinase 3 | 1 | 2023 | 127 | 0.060 |
Why?
|
| Prognosis | 2 | 2023 | 3679 | 0.050 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2023 | 138 | 0.050 |
Why?
|
| Tumor Burden | 1 | 2023 | 289 | 0.050 |
Why?
|
| Cyclophosphamide | 1 | 2023 | 299 | 0.050 |
Why?
|
| Risk Factors | 3 | 2017 | 5417 | 0.050 |
Why?
|
| Neoplasms | 1 | 2017 | 2898 | 0.050 |
Why?
|
| Atrial Function, Left | 1 | 2021 | 46 | 0.050 |
Why?
|
| Cell- and Tissue-Based Therapy | 1 | 2021 | 49 | 0.050 |
Why?
|
| Allografts | 1 | 2021 | 172 | 0.050 |
Why?
|
| Hydrazines | 1 | 2020 | 30 | 0.050 |
Why?
|
| Health Planning Guidelines | 1 | 2019 | 24 | 0.050 |
Why?
|
| Chimerism | 1 | 2020 | 37 | 0.050 |
Why?
|
| Arrhythmias, Cardiac | 1 | 2021 | 187 | 0.040 |
Why?
|
| Triazoles | 1 | 2020 | 96 | 0.040 |
Why?
|
| Heart Atria | 1 | 2021 | 250 | 0.040 |
Why?
|
| Health Plan Implementation | 1 | 2019 | 56 | 0.040 |
Why?
|
| Hematopoietic Stem Cells | 1 | 2021 | 292 | 0.040 |
Why?
|
| Aged, 80 and over | 2 | 2020 | 6509 | 0.040 |
Why?
|
| Standard of Care | 1 | 2019 | 79 | 0.040 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2023 | 589 | 0.040 |
Why?
|
| Myeloablative Agonists | 1 | 2017 | 34 | 0.040 |
Why?
|
| Palliative Care | 1 | 2019 | 257 | 0.040 |
Why?
|
| Clinical Decision-Making | 1 | 2019 | 257 | 0.040 |
Why?
|
| Betacoronavirus | 1 | 2020 | 258 | 0.040 |
Why?
|
| Pilot Projects | 1 | 2020 | 839 | 0.040 |
Why?
|
| Immunoglobulin Isotypes | 1 | 2017 | 32 | 0.040 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2017 | 348 | 0.030 |
Why?
|
| Patient Selection | 1 | 2019 | 685 | 0.030 |
Why?
|
| Feces | 1 | 2017 | 319 | 0.030 |
Why?
|
| T-Lymphocytes | 1 | 2020 | 1195 | 0.030 |
Why?
|
| Combined Modality Therapy | 1 | 2017 | 1686 | 0.030 |
Why?
|
| Age Factors | 1 | 2017 | 1851 | 0.030 |
Why?
|
| Disease-Free Survival | 1 | 2015 | 1204 | 0.030 |
Why?
|
| Neoplasm Staging | 1 | 2017 | 1939 | 0.030 |
Why?
|
| United States | 1 | 2021 | 6672 | 0.020 |
Why?
|